Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 14, 2022 07:30 ET | Source: Biogen Inc.

Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference

First patient treated in the ASCEND study evaluating the potential benefit of investigational higher dose nusinersen in children, teens and adults previously treated with Evrysdi® (risdiplam)Baseline...
March 11, 2022 16:30 ET | Source: Biogen Inc.

Biogen to Present New Research at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022)

CAMBRIDGE, Mass., March 11, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company will present new Alzheimer’s disease research, as well as data for ADUHELM® (aducanumab-avwa)...
February 07, 2022 16:05 ET | Source: Biogen Inc.

Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis

CAMBRIDGE, Mass and SOLNA, Sweden, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Xbrane Biopharma AB (STO: XBRANE) today announced that they have entered into a commercialization...
February 01, 2022 07:30 ET | Source: Biogen Inc.

Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody

Mosunetuzumab is an investigational T-cell engaging bispecific antibody targeting CD20 and CD3 in development for B-cell non-Hodgkin’s lymphoma and other therapeutic areas CAMBRIDGE, Mass., Feb. 01,...
January 31, 2022 07:30 ET | Source: Biogen Inc.

Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors

CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that Nancy Leaming and Brian Posner will retire from Biogen’s Board of Directors, effective at the time...
January 27, 2022 18:50 ET | Source: Biogen Inc.

Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion

CAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that they have entered into an agreement whereby Samsung Biologics will acquire Biogen’s equity stake in...
January 27, 2022 07:30 ET | Source: Biogen Inc.

Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®

CAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced additional details about the Phase 4 post-marketing confirmatory...
January 04, 2022 07:34 ET | Source: Biogen Inc.

Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA

BIIB115 is a preclinical investigational antisense oligonucleotide (ASO) that may have the potential for extended dosing intervalsBiogen paid Ionis a $60 million one-time upfront payment CAMBRIDGE,...
December 22, 2021 07:30 ET | Source: Biogen Inc.

Japan’s First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains under Review

CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the First Committee on New Drugs (NDC) of the Pharmaceutical...
December 20, 2021 07:00 ET | Source: Biogen Inc.

Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer’s Disease

CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that, effective January 1, 2022, it will reduce the wholesale acquisition cost (WAC) of ADUHELM®...